Status:
UNKNOWN
Droperidol on Prevention of Cannabis Hyperemesis Syndrome
Lead Sponsor:
Mercy Health Ohio
Collaborating Sponsors:
Lake Erie College of Osteopathic Medicine
Conditions:
Cannabis Hyperemesis Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.
Detailed Description
Patients presenting to the Emergency Department with nausea, vomiting and/or abdominal pain with a significant history of cannabis use and symptoms in a cyclic pattern will be assessed for study inclu...
Eligibility Criteria
Inclusion
- aged 18 years of age or older and presenting with cannabis hyperemesis syndrome requiring intravenous medication.
Exclusion
- any patient with a contraindication to the use of droperidol
- Corrected QT interval on ECG greater than 440 milliseconds for males and greater than 450 milliseconds for females
- any prisoners
- pregnant females.
Key Trial Info
Start Date :
December 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2023
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05244460
Start Date
December 2 2021
End Date
January 31 2023
Last Update
January 20 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Mercy Health - Austintown
Austintown, Ohio, United States, 44515
2
St Elizabeth Boardman Hospital
Boardman, Ohio, United States, 44512
3
St. Joseph-Warren Hospital
Warren, Ohio, United States, 44484
4
St Elizabeth Youngstown Hospital
Youngstown, Ohio, United States, 44501